BJMO - volume 12, issue 2, march 2018
W. Lybaert MD, P. Clement MD, PhD, K. Punie MD, J. Mebis MD, M. Renard MD, H. Wildiers MD, PhD
Chemotherapy-induced nausea and vomiting remains an important adverse effect of treatment in daily clinical practice. Recently, new data on combinations of antiemetic agents became available for the prevention of acute and delayed nausea/vomiting in patients receiving highly and moderately emetogenic chemotherapy. As a result, the leading international cancer societies updated their antiemesis guidelines. This text aims at providing guidance regarding these new regimens in the prophylaxis of chemotherapy-induced nausea and vomiting, with a particular focus on highly emetogenic chemotherapy.
(BELG J MED ONCOL 2018;12(2):51–60)
Read moreBJMO - volume 12, issue 3, february 2018
T. Vandamme MD, PhD, Isabelle Maurissen , W. Lybaert MD, Marc Simoens , P. Abrams , A. Driessen MD, PhD, B. Op de Beeck , Wim Demey MD, T. Rondou , M. Ulenaers , G. Vanhoutte , Marc Peeters , Steering Committee , NET-specialists
BJMO - volume 12, issue 3, february 2018
T. Vandamme MD, PhD, W. Lybaert MD, Marc Simoens , Wim Demey MD, T. Rondou , P. Abrams , C. Mattelaer , B. Op de Beeck , O. D’Archambeau , G. Roeyen MD, PhD, Lesley De Backer , Marc Peeters , Steering Committee , NET-specialists
BJMO - volume 12, issue 3, february 2018
B. De Laere PhD, Markus Mayrhofer , T. Whitington , P-J. Van Dam MD, P. Van Oyen , C. Ghysel , J. Ampe , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , Nick Beije , Inge De Kruijff , S. Oeyen , A. Rutten MD, V. Van Dam , A. Brouwer , D. Goossens , Lien Heyrman , G. Van Den Eynden MD, PhD, J. Vandebroek , Jurgen Del-Favero , S. Sleijfer , A. Uhlen , Jeffrey Yachnin , S. Van Laere PhD, Henrik Grönberg , Johan Lindberg , L. Dirix MD
BJMO - volume 11, issue 7, november 2017
W. Lybaert MD
In this article, the most important new studies presented at ESMO 2017 in Madrid in early (EBC) and metastatic breast cancer (MBC) are summarised. In EBC, 5 topics are highlighted: integration of PI3K and CDK4/6 inhibition in the neoadjuvant treatment of oestrogen receptor positive (ER+) EBC, dual endocrine blockade as adjuvant treatment in ER+ EBC, escalated adjuvant treatment in human epidermal growth factor receptor positive (HER2+) EBC and small tumours that can also show an aggressive course. In MBC, 4 topics are discussed: predicting immunogenicity in MBC, abscopal effect in MBC, confirmed benefit of PARP inhibitors in BRCA mutated MBC and CDK4/6 inhibition in first-line MBC.
(BELG J ONCOL 2017;11(7):309–314)
Read moreBJMO - volume 11, issue 3, may 2017
W. Lybaert MD, M. Simoens , Wim Demey MD, F. van Fraeyenhove MD, T. Vandamme MD, PhD, L. De Backer , M. Peeters MD, PhD
Barcelona, 8-10 March 2017.
(BELG J MED ONCOL 2017;11(3):129–133)
Read moreBJMO - 2017, issue 3, february 2017
L. Jongen , P. Neven MD, PhD, A. Lintermans , K. Van Asten MSc, C. Blomme , D. Lambrechts PhD, A. Poppe , H. Wildiers MD, PhD, A.S. Dieudonné , J. Decloedt MD, P. Berteloot , D. Verhoeven MD, PhD, M. Joerger , P. Vuylsteke MD, W. Wynendaele MD, PhD, M. Casteels , Sabine Van Huffel , W. Lybaert MD, J. Van Ginderachter , R. Paridaens , I. Vergote MD, PhD, V. Dezentjé , B. Van Calster PhD, H-J. Guchelaar
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
